Skip to Main Content

Paper Details

Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes.
J Pharmacol Exp Ther
11
2019
CK, CSF-1, Colony-Stimulating Factor-1 Antibody Lacnotuzumab, Lacnotuzumab, anti-CSF-1 monoclonal antibody, colony-stimulating factor-1, creatine, creatine kinase, humanized, lacnotuzumab, periorbital swelling
Author NameAffiliation
Francois PognanNovartis Pharma AG, U.S.) and Novartis Institutes for BioMedical Research
Philippe CouttetNovartis Pharma AG, U.S.) and Novartis Institutes for BioMedical Research
Ronenn RoubenoffNovartis Pharma AG, U.S.) and Novartis Institutes for BioMedical Research
  • 1 - 3

Datasets

Release 1.2